Healthcare provider profile · identity verified

Esther Lin, MD

Family Practice · RANSON, WV · NPI 1447741038

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	290	86
Rosuvastatin Calcium	Rosuvastatin Calcium	265	77
Levothyroxine Sodium	Levothyroxine Sodium	230	60
Amlodipine Besylate	Amlodipine Besylate	222	73
Lisinopril	Lisinopril	218	69
Albuterol Sulfate Hfa	Albuterol Sulfate	216	67
Gabapentin	Gabapentin	206	35
Metformin Hcl	Metformin Hcl	186	48
Losartan Potassium	Losartan Potassium	183	60
Omeprazole	Omeprazole	158	51
Hydrochlorothiazide	Hydrochlorothiazide	154	43
Famotidine	Famotidine	143	45
Ozempic	Semaglutide	137	20
Fluticasone Propionate	Fluticasone Propionate	121	44
Pantoprazole Sodium	Pantoprazole Sodium	114	37
Alendronate Sodium	Alendronate Sodium	111	35
Montelukast Sodium	Montelukast Sodium	110	28
Metoprolol Succinate	Metoprolol Succinate	108	35
Trazodone Hcl	Trazodone Hcl	105	31
Carvedilol	Carvedilol	102	29
Olmesartan Medoxomil	Olmesartan Medoxomil	89	33
Venlafaxine Hcl Er	Venlafaxine Hcl	89	27
Duloxetine Hcl	Duloxetine Hcl	86	22
Metformin Hcl Er	Metformin Hcl	86	24
Furosemide	Furosemide	80	25
Januvia	Sitagliptin Phosphate	78	22
Meloxicam	Meloxicam	74	21
Allopurinol	Allopurinol	70	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	70	23
Pravastatin Sodium	Pravastatin Sodium	68	20
Pioglitazone Hcl	Pioglitazone Hcl	65	18
Sertraline Hcl	Sertraline Hcl	64	22
Eliquis	Apixaban	62	17
Tamsulosin Hcl	Tamsulosin Hcl	59	20
Bupropion Xl	Bupropion Hcl	54	12
Breo Ellipta	Fluticasone/Vilanterol	53	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	50	15
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	50	13
Spiriva Handihaler	Tiotropium Bromide	49	12
Symbicort	Budesonide/Formoterol Fumarate	49	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	48	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	47	14
Buspirone Hcl	Buspirone Hcl	46	19
Quetiapine Fumarate	Quetiapine Fumarate	46	12
Tramadol Hcl	Tramadol Hcl	45	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	43	11
Solifenacin Succinate	Solifenacin Succinate	40	17
Simvastatin	Simvastatin	39	12
Topiramate	Topiramate	39	suppressed
Citalopram Hbr	Citalopram Hydrobromide	35	suppressed
Incruse Ellipta	Umeclidinium Bromide	33	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	33	12
Clopidogrel	Clopidogrel Bisulfate	32	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	32	suppressed
Mirtazapine	Mirtazapine	32	suppressed
Clonazepam	Clonazepam	31	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	30	11
Ibuprofen	Ibuprofen	27	suppressed
Ropinirole Hcl	Ropinirole Hcl	27	suppressed
Irbesartan	Irbesartan	26	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	26	suppressed
Alprazolam	Alprazolam	25	suppressed
Azelastine Hcl	Azelastine Hcl	25	12
Pregabalin	Pregabalin	25	suppressed
Chlorthalidone	Chlorthalidone	24	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	24	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	24	suppressed
Jardiance	Empagliflozin	24	suppressed
Nystatin	Nystatin	24	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	11
Ventolin Hfa	Albuterol Sulfate	23	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	21	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	20	suppressed
Glimepiride	Glimepiride	20	suppressed
Glipizide	Glipizide	20	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	20	suppressed
Nitroglycerin	Nitroglycerin	19	12
Ondansetron Odt	Ondansetron	19	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	19	suppressed
Bupropion Hcl Sr	Bupropion Hcl	18	suppressed
Estradiol	Estradiol	18	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	18	suppressed
Mounjaro	Tirzepatide	18	suppressed
Atenolol	Atenolol	17	suppressed
Diazepam	Diazepam	17	suppressed
Donepezil Hcl	Donepezil Hcl	17	suppressed
Lovastatin	Lovastatin	17	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	17	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	17	suppressed
Tizanidine Hcl	Tizanidine Hcl	17	suppressed
Aripiprazole	Aripiprazole	16	suppressed
Rybelsus	Semaglutide	16	suppressed
Trulicity	Dulaglutide	16	suppressed
Ezetimibe	Ezetimibe	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Spironolactone	Spironolactone	15	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	14	suppressed
Cephalexin	Cephalexin	14	11
Janumet	Sitagliptin Phos/Metformin Hcl	14	suppressed
Mupirocin	Mupirocin	14	suppressed
Primidone	Primidone	14	suppressed
Varenicline Tartrate	Varenicline Tartrate	14	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	13	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	13	suppressed
Ipratropium Bromide	Ipratropium Bromide	13	suppressed
Temazepam	Temazepam	13	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	12	suppressed
Cilostazol	Cilostazol	12	suppressed
Diclofenac Sodium	Diclofenac Sodium	12	suppressed
Invokana	Canagliflozin	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	12	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	12	suppressed
Vascepa	Icosapent Ethyl	12	suppressed
Warfarin Sodium	Warfarin Sodium	12	suppressed
Xarelto	Rivaroxaban	12	suppressed
Celecoxib	Celecoxib	11	suppressed
Glipizide Er	Glipizide	11	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed
Sucralfate	Sucralfate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error